News

Cystatin C May Be a Biomarker for Diabetic Nephropathy


 

Thirteen percent of patients progressed to microalbuminuria during 7 years of follow-up. A high-risk subgroup consisting of 8% of the patient population was identified as having a risk of progression of 32% (Diabetologia 2010;53:254-62).

Dr. Maahs disclosed receiving research support from Merck and Eli Lilly.

Pages

Recommended Reading

Colorectal Cancer Risk Higher for Diabetic Men
MDedge Family Medicine
Diabetes Education Cut Hospital Admissions
MDedge Family Medicine
Oxidized LDL May Predict CV Disease Risk
MDedge Family Medicine
What's New in Insulins and Delivery Systems : Intranasal, buccal, oral, peritoneal, and even rectal insulins are in various stages of development.
MDedge Family Medicine
Data Watch: Diabetes Patients Aged 40 and Over Who Received All Three Recommended Services* for diabetes in 2006
MDedge Family Medicine
Diabetes Screening May Lower CV Event Risk
MDedge Family Medicine
Metabolic Syndrome Alone May Raise CVD Risk
MDedge Family Medicine
Lifestyle Intervention Worked Well in Diabetes
MDedge Family Medicine
Metformin's Anticancer Potential Is Generating a Buzz
MDedge Family Medicine
BP, Gait Linked to Cognitive Deficits in Type 2
MDedge Family Medicine